NDAORALTABLET
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HARMONYL (deserpidine) is an oral tablet antihypertensive agent approved in 1957 as an NDA product. Deserpidine is a Rauwolfia alkaloid derivative used to treat hypertension. The mechanism of action involves sympathetic nervous system depression, lowering blood pressure through reduced vascular resistance.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal linked career positions, this asset likely operates with a small maintenance team focused on portfolio retention rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HARMONYL represents a legacy portfolio asset with minimal career dynamism; roles are maintenance-focused rather than growth-oriented. Professionals joining this product should expect primarily operational responsibilities managing an established but declining franchise within AbbVie's hypertension portfolio.
Portfolio ManagerBrand Manager
Worked on HARMONYL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.